San Francisco, CA
Dr. Thierry Marie Jahan
Lung Cancer Specialist
Columbia University - 1983
George Washington University School of Medicine - 1987
Cedars-Sinai Medical Center/UCLA
Sinai Medical Center/ UCLA Division of General Internal Medicine; University of California at San Francisco
Dr. Thierry Marie Jahan began his medical career over 20 years ago after completing an undergraduate degree at Columbia University. He then earned a medical degree form The George Washington University School of Medicine in Washington, D.C. Dr. Jahan began his Residency in the Department of Medicine at Cedars-Sinai Medical Center/UCLA in Los Angeles, California. He went on to complete his Kennamer/ General Internal Medicine Fellowship at the Sinai Medical Center/ UCLA Division of General Internal Medicine in the Department of Medicine. Dr. Jahan finished his Clinical Fellowship in 1994 at the University of California at San Francisco in the Division of Hematology/Oncology, Department of Medicine.
Dr. Jahan entered the academic field when he became an Assistant Clinical Professor at the University of California at San Francisco in the Division of Hematology/Oncology. He later became Associate Clinical Professor of Medicine and Director of Clinical Services in the Division of Hematology/ Oncology at UCSF Helen Diller Family Comprehensive Cancer Center at the Mount Zion campus in San Francisco.
Today, Dr. Jahan continues his work at the University of California San Francisco as a Clinical Professor of Medicine. He is dedicated to the treatment of mesothelioma, lung cancer, sarcomas and endocrine tumors with multiple treatment options. He also specializes in the study of new treatments for malignancies for illnesses related to the chest while continuing to care for his patients.
In this video, Dr. Thierry Jahan talks about “a new wind of hope” that is now available for Lung Cancer and Mesothelioma patients. He discusses new, state of the art molecular analyses and specifically designed drugs that target exactly the disease and very little else. This results in far fewer side effects, improved quality of life and longer life expectancy for those suffering with these diseases.
Dr. Jahan has authored and co-authored a number of scholarly texts including, "Small cell lung cancer clinical practice guidelines in oncology," published in the Journal of the Comprehensive Cancer Network in 2006. That same year he also published, "Non-small cell lung cancer clinical practice guidelines in oncology," in the same publication. In the study of mesothelioma, Dr. Jahan co-authored the abstract, "Vatalanib (V) in malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B," for the American Society of Clinical Oncology.
Awards and Affiliations
In 1996 Dr. Jahan was given the Outstanding Teacher Award from the University of California San Francisco, Mount Zion Medical Center. He was also the 1st Annual Friend of the Palliative Care Service Award in 2006.
As a member of a number of professional organizations, Dr. Jahan is a participant of the American College of Physicians, the American Society of Clinical Oncology, The International Association for the Study of Lung Cancer and the Association of Northern California Oncologist.
U of California at San Francisco Cancer Center